


# Recurrence or Relapse of COVID-19 in Older Patients

**Shima Raeesi, MD**

**Geriatrician**



**۷۵,۱۱۰,۶۵۱ confirmed cases of COVID-۱۹,  
۱,۶۸۰,۳۹۵ deaths**



- Isolation and containment are the main measures to break chain contamination in primary prevention.
- The tertiary prevention is based on the assumption of **effective immunization of infected individuals** to prevent recurrence of the infection.
- The first cases of possible **reinfection** by SARSCoV-2 were reported in April 2020 among adults.

# **Recurrence or relapse of the SARS-CoV-2 infection in a series of older patients**

**Saint-Etienne, France**

# Patient \

An 84-year-old woman

## Medical history:

- High blood pressure
- Heart failure
- Atrial fibrillation treated by rivaroxaban
- Diabetes mellitus, type II, treated with insulin
- Chronic renal failure
- Chronic respiratory failure under long-term oxygen (15 h a day)

# Patient \

- **Cough** and **fever**
- Oxygen desaturation at 79%
- Biological markers:
  - CRP: 11 mg/L
  - Lymphocyte count: 1.1 cells/L
  - Neutrophil count: 11.1 cells/L

# Patient 1

- Computed tomographic (CT) scan: **Bilateral ground glass lesions** predominating on the right lung. (March 24)
- **Positive SARS-CoV-2 RT-PCR** (Nasopharyngeal sample) (March 24)  
Cycle threshold (Ct): 31.4

Hospitalized in  
an acute-care  
unit

Levofloxacin (7  
days)

Short course of  
corticosteroids

Clinical and  
biological  
improvements

COVID-19  
rehabilitation  
care unit (April 7)

CRP and  
lymphocyte rate  
were normalized






# Patient 1

On May 2 (more than 1 month after the first episode):

- **Hyperthermia** and **respiratory signs**
- Readmitted into an acute-care unit dedicated to COVID-19
- SARS-CoV-2 RT-PCR tests (May 3) in nasopharyngeal swab and sputum, and were **positive** (Ct of 17.5 and 18.1)

# Patient 1



# Patient 1

- Biological **inflammatory syndrome**
  - CRP: 30.4,5 mg/L
  - Deep lymphopenia (470 cells/L)
  - Interleukin (IL)-6: 235 ng/L
- Neutralizing antibodies to SARS-CoV-2 were **negative** on May 8 and faintly positive (rate of 1:10) on May 15



# Patient 1

- Oxygen therapy
- Noninvasive ventilation (May 12)
  
- Levofloxacin (May 5)
- Aztreonam (May 8)
  
- Methylprednisolone, 60 mg/d (May 10)
  
- Tocilizumab (8 mg/kg) (May 12)

# Patient \

- Finally died on May 17
- Respiratory and heart failure despite high-dose furosemide



# Patient ۲

- A ۹۰-year-old dependent woman
- Living in a nursing home
  
- Medical history:
  - Diabetes mellitus, type II
  - Hypertension
  - Hypothyroidism
  - Alzheimer's disease

# Patient ۲

In early April ۲۰۲۰:

- Cardiorespiratory decompensation
- Atrial fibrillation
- Fever

# Patient ۲

- Biological markers:
  - CRP: ۵۵ mg/L
  - Lymphocyte count: ۱۶۷۰ cells/L
  - Neutrophil count: ۷۲۹۰ cells/L
- SARS-CoV-۲ RT-PCR positive test on a nasopharyngeal specimen (April ۵)  
(Ct of ۲۱)



# Patient ۲



COVID-19 acute-care unit

Preventive anticoagulation

Diuretics

Ofloxacin

Prednisolone

COVID-19 rehabilitation care unit

(April 21)

Return to the nursing home (May 2)

- CRP stable at 55
- Chronic pressures sores



# Patient 2

On May 11:

- Major dehydration
- Hyponatremia (166 mmol/L)
- Oxygen saturation at 93% under 4 L of oxygen
- Melena
- Marked deterioration of her general condition
- Marked lymphopenia (180 cells/L)
- CRP: 181 mg/L
- The SARS-CoV-2 RT-PCR test was positive on a nasopharyngeal swab.  
Ct at 18.8

# Patient ۲

On May ۱۴



# Patient ۲

- Palliative care
- The patient finally died on May ۱۹



# Patient ۲

An ۸۴-year-old woman


Medical history:

- **Rhythmic heart disease** treated with a pacemaker
- **Pulmonary embolism** treated with rivaroxaban
- **Hypertension**
- **Rheumatoid arthritis** treated with methotrexate, ۱۵ mg/wk and corticosteroids (prednisone, ۱۳ mg/d)

# Patient ۲

- Fever
- Asthenia
- Ageusia
- Dry cough
- Polypnea (۳۲ /min)
- Oxygen desaturation with ۹۳% under ۳ L of oxygen

# Patient ۲





# Patient ۲

- CRP: ۳۱.۵ mg/L
- Lymphocytes: ۷۳۰ cells/L
- The SARS-CoV-۲ RT-PCR test performed on nasopharyngeal sample was **negative twice**
- **No other infectious cause** was found
- Sputum could not be collected

- **Oxygen withdrawal**
- **Normalization of the inflammatory syndrome**



- **Discontinuation of methotrexate treatment**
- **Replaced by an increase in corticosteroids (prednisone = 30 mg/d)**

# Patient ۲

On May ۶: **Sudden respiratory deterioration**

- ۸۰% desaturation requiring oxygen therapy
- Dry cough
- Fever
- Nasopharyngeal samples for SARS-Cov-۲ RT-PCR test were found positive.  
(Ct at ۱۶.۹ and ۱۴.۷ on May ۸ and ۱۱, respectively)

# Patient ۳



# Patient 2

At readmission:

- Marked lymphopenia: 230 cells/L
- CRP: 146 mg/L
- IL-6: 2.1 ng/L
- A rise of neutralizing antibodies against SARS-CoV-2 was observed from May 8 to May 15 (titers from <10 to 40)

# Patient ۳

- Ceftriaxone
- Methylprednisolone, ۶۰ mg/d
- High-flow oxygen
  
- ۱۱ days later: **Cotrimoxazole** (Pneumocystosis superinfection)
  
- After validation in a multidisciplinary meeting: **Convalescent COVID-۱۹ plasma transfusion**

# Patient ۲

- The respiratory status deteriorated
- Major desaturation despite ۲۰ L of oxygen
- She finally died on May ۲۳



# Clinical and Laboratory Characteristics

Characteristics	Patient 1	Patient 2	Patient 3
<b>General characteristics</b>			
Age, y	84	90	84
Sex	F	F	F
Comorbidities	Yes	Yes	Yes
Diabetes mellitus, type II		<input checked="" type="checkbox"/>	
Arterial hypertension	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Heart disease	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Cancer	<input checked="" type="checkbox"/>		
Chronic obstructive pulmonary disease	<input checked="" type="checkbox"/>		
Immunosuppression			<input checked="" type="checkbox"/>
<b>COVID-19 (first time)</b>			
Diagnosis of COVID-19	Yes	Yes	Yes
SARS-CoV-2 PCR test	Yes/Mar 26	Yes/Apr 5	No/Apr 15
Chest CT scan	Yes/Mar 24	No/Apr 5	Yes/Apr 16
<b>Biological markers</b>			
Neutrophil count, $\times 10^9$ cells/L	2.77	8.23	6.17
Lymphocyte count, $\times 10^9$ cells/L	0.77	2.16	0.13
C-reactive protein, mg/L	88	47	160
Treatments received	Yes	Yes	Yes
Antiviral therapy			
Antibiotics	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Corticosteroids	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Death	No	No	No



# Clinical and Laboratory Characteristics

Biological markers before the second COVID-19			
Neutrophil count, $\times 10^9$ cells/L	5.98	7.29	10.41
Lymphocyte count, $\times 10^9$ cells/L	1.27	1.67	0.73
C-reactive protein, mg/L	8.7	55	31.5
COVID-19 (second time)			
Diagnosis of COVID-19	Yes	Yes	Yes
SARS-CoV-2 PCR test	Yes/May 6	Yes/May 6	Yes/May 7
Chest CT scan	Yes/May 4	Yes/May 14	Yes/May 7
Biological markers			
Neutrophil count, $\times 10^9$ cells/L	11.96	11.64	10.93
Lymphocyte count, $\times 10^9$ cells/L	0.47	0.89	0.23
C-reactive protein, mg/L	304.5	181	146.9
IL-6, ng/L	235		201
Treatments received	Yes	Yes	Yes
Antiviral therapy			
Antibiotics	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Corticosteroids	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Immunotherapy	<input checked="" type="checkbox"/>	-	<input checked="" type="checkbox"/>
Death	Yes/May 17	Yes/May 19	Yes/May 23

# Discussion

- Two episodes of COVID-19
- Separated by a symptom-free interval of weeks
- SARS-CoV-2 reinfection or COVID-19 relapse?

# Discussion

- **Viral replication** was found during the second episode in all three cases
- All virological and bacteriological infectious samples were **negative**, except for COVID-19
- The three women were placed in **isolation rooms** in hospital units dedicated to COVID-19, with caregivers trained and equipped to comply with the isolation measures
- The **symptom-free interval was relatively short**
- The hypothesis of **reinfection with a new strain is also unlikely**

# Discussion

- A **relapse of COVID-19** seems to be the preferred hypothesis that would yet need **comparisons of strains** with sequencing to be affirmed.
- The absence of antibodies presented at readmission for two of the three patients is in favor of a **possible reactivation**.

# Discussion

- The **immune reaction** may be the cause of clinical deterioration
- One hypothesis would be that these episodes are linked to the **persistence of the virus in a reservoir** (sanctuary site).
- **Immunosenescence** would have a role in the observed clinical pictures, with a possible nonresponse at the time of the first COVID-19 episode.

# Discussion

- The three cases we present here **did not received diagnostic tests**, supposedly negative, during the transient improvement in clinical signs.
- **Prolonged infections** and **reactivations**
- If the risk of recurrence is confirmed, it will be crucial to analyze the **risk factors** (comorbidities, undernutrition, lymphopenia, and weak immune reaction with a low or even negative serology) but also their **severity**.

# Discussion

- It can be assumed that the **cytokine storm** could be **greater** than during the first contamination, leading to more serious and more frequently lethal forms.
- In the case of the second wave, special attention should be paid to older patients who were affected by COVID-19 during the first wave.

